Board of Directors

amit-kumar-ph-d
Amit Kumar, Ph.D. Chairman & Chief Executive Officer

Dr. Kumar has been an investor, founder, director and CEO of several technology enterprises, both public and private. As CEO, he took CombiMatrix Corporation public and ran it for a decade while listed on the NASDAQ Global Market. He has worked in venture capital with OAK Investment Partners, and has ...

Read More

lew-titterton
Lew Titterton Lead Independent Director

Mr. Titterton previously served as a Director from August 2010 through August 2016, the last four years of which as Chairman of the Board. He also served as a Director from July 1999 to January 2003. Mr. Titterton's background is in high technology with an emphasis on health care. He ...

Read More

arnold-baskies-md
Arnold Baskies, MD Director

Dr. Baskies, former Chairman of the national Board of Directors of the American Cancer Society, is a fellowship trained surgical oncologist with special interests in breast cancer, thyroid cancer, and melanoma. He received his Bachelor of Arts degree summa cum laude and was a member of Phi Beta Kappa at ...

Read More

emily-gottschalk
Emily Gottschalk Director

Emily Gottschalk is an experienced marketer with over 30 years of developing products for the consumer marketplace. She is the founder and CEO of The Garr Group, Inc, a diverse entertainment and new product development company that sells entertainment and general merchandise to the mass, specialty and on-line market. Mass ...

Read More

Sign up for email Updates

Be The First to Receive Breaking News

Sign Up Now
Logo Itus

Latest News & Events

Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial

Read More...

Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Read More...

Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Read More...